Fibromyalgia: What's the Deal? (Second Edition)
This program is worth up to 2.0 CME credits.
Fibromyalgia is a term that often conjures up images of patients who "complain" about pain and so many other symptoms. It is often difficult to diagnose and treat patients with fibromyalgia, partly because of the lack of a clearly understood patho-physiologic basis and partly because of difficulty communicating with these patients about their multiple symptoms. However, patients with fibromyalgia do end up in the neurologist's office with chronic widespread pain and it is the duty of the physician to make an appropriate diagnosis and treatment plan. This course will address the many facets of fibromyalgia, from the nuts and bolts like epidemiology, diagnosis and treatment, as well as the more challenging issues like communication, pathophysiology and alternative therapies. It is our hope that after you take this course, you will have a better understanding of this disorder in general, be more comfortable making and discussing the diagnosis and achieve success at improving the suffering of your patients' who are affected by this condition. Whether or not you buy into whether this is a "real" disease or a symptom complex, the patients who suffer with these issues clearly exist and frequently see neurologists along the way.
Up to 2.0 CME credits
*Free access is limited to one course at a time for eligible members.
As a result of this program the learner will:
Make an early and accurate diagnosis of fibromyalgia, discuss the diagnosis with the patient and initiate an effective treatment plan. Specifically:
- Identify patients with fibromyalgia and initiate a comprehensive multimodal treatment plan
- Understand the neurologic basis of the disorder and able to tease out comorbidities
- Educate patients and caregivers about the nature and management of fibromyalgia
- Patient Care
- Interpersonal and Communication Skills
- Medical Knowledge
Date of Release
September 15, 2015
This module is eligible for CME credits for three years from the release date.
Confidentiality of Data
All material © American Academy of Neurology Institute unless otherwise indicated. All rights reserved.
Faculty & Disclosures
JOSEPH E. SAFDIEH, MD, FAAN
Associate Professor of Neurology
Weill Medical College of Cornell University
New York, New York
*Dr. Safdieh has nothing to disclose.
Unlabeled Use DisclosureGabapentin, tricyclic antidepressants, tramadol and selective serotonin reuptake inhibitors are not FDA approved for treating fibromyalgia, but will be discussed off-label.
AttributionWith thanks to Jacqueline B. Stone, MD for her contributions.
*Dr. Stone has nothing to disclose.
A. GORDON SMITH, MD, FAAN
University of Utah Department of Neurology
Salt Lake City, Utah
*Dr. Smith has received personal compensation for activities with Allergan, Baxter Bioscience, Merz, Pfizer and NeurogesX as a consultant..
Maureen Holtzman, Senior Manager, Education
*Ms. Holtzman has nothing to disclose.
Tracy King, MA, Senior Manager, Education
*Ms. King has nothing to disclose.
Robert Rook, Program Manager, Digital Education Resources
*Mr. Rook has nothing to disclose.
Jodi Brenden Amir, Program Manager, Distance Learning
*Ms. Brenden Amir has nothing to disclose.
Susan Rodmyre, Director, Education
*Ms. Rodmyre has nothing to disclose.
Kurt Wiersma, Senior Manager, Web Development
*Mr. Wiersma has nothing to disclose.
Lori Strachota, Program Manager, Conference Management, Registration
*Ms. Strachota has nothing to disclose.